Bioabsorbable Drug-Eluting Stent Treats Coronary Artery Disease
By HospiMedica International staff writers Posted on 13 Oct 2015 |
A novel bioabsorbable polymer drug-eluting stent system (BP-DES) provides synchronized drug and polymer absorption to enable more rapid and complete arterial healing.
The SYNERGY BP-DES is an everolimus-eluting platinum chromium coronary stent system that features an ultra-thin abluminal bioabsorbable poly (lactic-co-glycolic acid) (PLGA) polymer coating that is intended to reduce the risk of complications associated with long-term permanent polymer exposure, which are currently used in DES systems. The proprietary PLGA polymer completes absorption shortly after everolimus drug elution ends (at three months), leaving only the bare platinum chromium stent.
The platinum chromium alloy and enhanced stent design enable thinner struts and improved deliverability while maintaining excellent conformability, flexibility, radiopacity, and low recoil. The technology provides the same level of restenosis reduction as a conventional everolimus-eluting stent, while offering faster and more complete vessel healing after implantation, potentially reducing duration of post-procedure dual antiplatelet therapy. The SYNERGY BP-DES is a product of Boston Scientific (Natick, MA, USA) and has been approved by the US Food and Drug Administration (FDA).
“In addition to its innovative coating, the foundation of the SYNERGY stent is our proprietary platinum chromium alloy and an enhanced stent design which allow for thinner struts, increased visibility and an extremely low crossing profile for easier deliverability,” said Kevin Ballinger, president of interventional cardiology at Boston Scientific. “The SYNERGY stent is a next generation therapy designed to improve patient outcomes and ultimately reduce health care costs associated with the treatment of coronary artery disease.”
Long-term exposure to polymer may cause inflammation, which delays healing and has been associated with other complications, including neoatherosclerosis and stent thrombosis.
Related Links:
Boston Scientific
The SYNERGY BP-DES is an everolimus-eluting platinum chromium coronary stent system that features an ultra-thin abluminal bioabsorbable poly (lactic-co-glycolic acid) (PLGA) polymer coating that is intended to reduce the risk of complications associated with long-term permanent polymer exposure, which are currently used in DES systems. The proprietary PLGA polymer completes absorption shortly after everolimus drug elution ends (at three months), leaving only the bare platinum chromium stent.
The platinum chromium alloy and enhanced stent design enable thinner struts and improved deliverability while maintaining excellent conformability, flexibility, radiopacity, and low recoil. The technology provides the same level of restenosis reduction as a conventional everolimus-eluting stent, while offering faster and more complete vessel healing after implantation, potentially reducing duration of post-procedure dual antiplatelet therapy. The SYNERGY BP-DES is a product of Boston Scientific (Natick, MA, USA) and has been approved by the US Food and Drug Administration (FDA).
“In addition to its innovative coating, the foundation of the SYNERGY stent is our proprietary platinum chromium alloy and an enhanced stent design which allow for thinner struts, increased visibility and an extremely low crossing profile for easier deliverability,” said Kevin Ballinger, president of interventional cardiology at Boston Scientific. “The SYNERGY stent is a next generation therapy designed to improve patient outcomes and ultimately reduce health care costs associated with the treatment of coronary artery disease.”
Long-term exposure to polymer may cause inflammation, which delays healing and has been associated with other complications, including neoatherosclerosis and stent thrombosis.
Related Links:
Boston Scientific
Read the full article by registering today, it's FREE!
Register now for FREE to HospiMedica.com and get complete access to news and events that shape the world of Hospital Medicine.
- Free digital version edition of HospiMedica International sent by email on regular basis
- Free print version of HospiMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of HospiMedica International in digital format
- Free HospiMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Critical Care News
- AI to Improved Diagnosis of Atrial Fibrillation
- Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment
- Machine Learning Tool Identifies Rare, Undiagnosed Immune Disorders from Patient EHRs
- On-Skin Wearable Bioelectronic Device Paves Way for Intelligent Implants
- First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD
- AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases
- Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time
- Wearable Multiplex Biosensors Could Revolutionize COPD Management
- New Low-Energy Defibrillation Method Controls Cardiac Arrhythmias
- New Machine Learning Models Help Predict Heart Disease Risk in Women
- Deep-Learning Model Predicts Arrhythmia 30 Minutes before Onset
- Breakthrough Technology Combines Detection and Treatment of Nerve-Related Disorders in Single Procedure
- Plasma Irradiation Promotes Faster Bone Healing
- New Device Treats Acute Kidney Injury from Sepsis
- Study Confirms Safety of DCB-Only Strategy for Treating De Novo Left Main Coronary Artery Disease
- Revascularization Improves Quality of Life for Patients with Chronic Limb Threatening Ischemia